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Abstract Sarcosinemia is a rare inborn error of metabo-
lism that is characterised by an increased level of sarcosine
(N-methylglycine) in the plasma and urine. The enzymatic
block results from a deficiency of sarcosine dehydrogenase
(SarDH), a liver mitochondrial matrix enzyme that converts
sarcosine into glycine. Although this condition may remain
inapparent until later life, it has been reported in rare cases
to lead to neurodevelopmental disability. A 19-year-old
male with sarcosinemia presented with dystonia, develop-
mental delay and cognitive impairment. Magnetic
resonance imaging revealed vermian hypotrophy. A 2-year
pharmacological treatment with memantine was negative
on the clinical signs. In this case, it was concluded that the
metabolic block leading to sarcosinemia was responsible of
a pathologic condition with mental deficiency and complex
neurological signs. A maternal isodisomy discovered in the
vicinity of SarDH gene could contribute to this pathology.
Deficit of SarDH may be considered as a differential
diagnosis of growth failure during prenatal stages and
respiratory failure at birth following a slowly progressive
developmental delay.
Introduction
Sarcosinemia (OMIM 268900) is a rare autosomal recessive
inborn error of the one-carbon metabolism, with increased
plasma level of sarcosine and high urine excretion.
Sarcosine (N-methylglycine) is synthesised from dimethyl-
glycine by dimethylglycine dehydrogenase and converted
to glycine by sarcosine dehydrogenase (SarDH), within the
mitochondrial matrix. Since the first case published in 1966
by Gerrsitsen and Waisman (1966), over around 30 patients
were reported. The presentation is mostly by mental delay,
but also cardiomyopathy, deafness and visual disturbance.
Occasionally, deficit of SarDH might remain asymptomatic
until later life (Christensen et al. 1989).
We report the case of 19 year old male in whom a
sarcosinemia was diagnosed on a complex neurological
syndrome developing progressively since childhood with a
history of developmental delay. A follow-up of 18 months
pharmacological trial is discussed.
Report of a Case
A 19 year young male was referred to our clinic because of
the worsening of his neurological condition. From the
parents, we learned that he had a long and progressive
history of neurological impairment. Our patient was
delivered prematurely at 34 weeks of uncomplicated
gestation to non-consanguineous parents. The infant was
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born small for date (weight 1,200 g, occipitofrontal
circumference 28 cm, length 43 cm; –2 s) but morpho-
logically normal. He required a short ventilatory support
because of mild respiratory difficulties and lethargy at birth.
Because of low growth and reduced sucking he stayed in a
continuous care unit during the first 2 months. Slight
intermittent dystonic posture of the right leg and muscular
hypotonia were noted in the first 14 months of his life. At
the age of two, he started to walk but did not speak. Since
the first school classes his education results were
considered as weak but he learned to write. He was
considered as awkward, with motor and speech disabilities
(intelligence quotient of 56 in verbal and 57 in perfor-
mance). Due to these difficulties, our patient had to attend a
specialised school. At about the age of 9, gait progressively
worsened due to dystonia and postural instability. He
showed emotional lability with rare violent outbursts and
behavioural problems. Around the age of 16, he progres-
sively developed a dysarthria with blurred and slow speech
and cerebellar ataxia. Otherwise, his neurological condition
remained stable, without any acute exacerbation. At the
age of 19, gait disturbance and dystonic movements
became permanent, leading to hospitalisation. The physical
parameters remained harmoniously low: occipitofrontal
circumference of 53 cm (–2 s), weight 43 kg (–3 s) and
height 163 cm (–1.7 s). Other neurological symptoms
included hyperreflexia without Babinski sign, hypotonia
and dystonia exaggerated by stress and present both at rest
and walking. There was a hollow foot with permanent
internal rotation of the right leg. The dystonic posture of the
body and the arms interfered with volitional movements
and resulted in a clumsy gait, dropping and spilling,
without losing ability to ambulate. Speech was slow,
lacking normal prosody. Ophthalmological investigation
revealed iris atrophy, congenital left eye cataract and poor
saccadic adaptation.
Until this late period, he was considered as having late-
onset atypical complications of a perinatal hypoxia, because
of the history of respiratory distress at birth followed by
complex neurological signs. However, since he was
hypotrophic at birth, we considered that a developmental
or metabolic illness should be considered. As such, we
performed detailed laboratory and brain imaging analysis.
The MRI showed mild vermian atrophia without signifi-
cant abnormality in the brainstem and the cerebrum or
abnormalities in the myelination (Fig. 1a, b). The spectral
profile within the pallidum was normal on a 1H magnetic
resonance spectrometry (1H-MRS) (Fig. 1c, d).
Basic neuropsychological evaluation performed using
standard test battery for intelligence, attention, visuo-spatial
and executive functions showed a moderate dysexecutive
syndrome with slow information processing speed,
impairment of attention and planification processes.
A 4 year follow-up showed a stable performance on global
intelligence quotient assessment.
Ancillary blood tests including folic acid were within the
reference intervals. A chromatography of urine showed an
increased excretion of sarcosine at 1,214 mmol/mmol of
creatinine. Excessive levels of sarcosine were found in
plasma (319 mmol/L) and in CSF (7 mmol/L). All other
amino acids were present at normal levels both in the
plasma and urine except a slightly higher excretion of
glycine considered as dependent of dietary factors (Table 1).
Studies for inborn metabolic errors including organic acids,
purines and pyrimidines, lactic and pyruvic acid were also
normal in plasma, urine and CSF, thus excluding a possible
glutaric aciduria type II. Thus, we raised the biochemical
diagnosis of possible sarcosinemia. We found no abnormal
blood and urine sarcosine levels in the other two siblings,
the mother or the father.
Since sarcosine is a potent competitive inhibitor of glycine
type 1 transporter (GlyT1) (Smith et al. 1992 May), we
hypothesised that neurological and cognitive impairment in
sarcosinemia could be related to an interference with NMDA
receptors. Thus an NMDA receptor antagonist such as
memantine could be considered as a symptomatic treatment
option. With the informed consent of his parents, a
memantine was given for 2 years (20 mg/day the first year,
then 40 mg/day), in addition to a rehabilitation programme
and orthopaedic treatment on the right leg. Loading tests
with folic acid or riboflavin were not performed because
of weak therapeutic efficiency reported (van Sprang et al.
1986).
No significant improvement of gait or cognitive
performances was noted during the period of treatment
with memantine. However, amino acid chromatography
analysis of plasma, urine and CSF during the trial revealed
some slight lowering of plasma levels and elevation in the
CSF (Table 1).
Comment
We present a patient with movement disorder and develop-
mental disabilities suggestive of brain damage where the
biochemical analysis revealed sarcosinemia. The incidence
of sarcosinemia is difficult to establish because as few as
30 cases were published during the last 50 years. No brain
imaging data or follow-up information is available for the
previously published cases. Since so few cases have been
reported with sparse clinical descriptions, a detailed clinical
phenotype could not be extracted from the literature.
The only common feature was a low cognitive global
performance. Although in some cases sarcosinemia was
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considered as a benign condition, usually a neurodevelop-
mental disability starts insidiously, before the brain is fully
mature, and progresses slowly over several years. Our patient
shares some symptoms (premature birth with respiratory
distress, short stature and mental retardation) with previously
reported cases of sarcosinemia. The neuropsychological
Fig. 1 A moderate antero-superior vermian atrophy on sagittal T1-
weighted (TR/TE 425 ms/10 ms) (a) and on a coronal section on T2-
weighted (b) brain MRI. The scan was performed before the
memantine treatment. (c) Proton MR spectroscopy (1H-MRS) at the
age of 21 (clinical system of 3T, TE: 30 ms, using commercially
available software) reveals no significant changes at short TE.
(d) Representative location of the MRS voxels on axial T2-weighted
image within the basal ganglia
Table 1 Results of biochemical analysis. Nd: not determined.
Amino acids Dec./ 07 Feb./ 08 Sept./08 Sept./09
Sarcosine (plasma) mmol/L (reference values <10) 319 326 379 238
Glycine (plasma) mmol/L (reference values ¼120–320) 254 255 291 310
Serine (plasma) mmol/L (reference values ¼ 50–200) 145 135 116 133
Sarcosine (urine) mmol/mmol of creatinine(reference values < 50) 1214 655 631 nd
Glycine (urine) mmol/mmol of creatinine(reference values ¼ 60–190) 419 236 198 nd
Serine (urine) mmol/mmol of creatinine(reference values ¼ 20–50) 77 52 38 nd
Sarcosine (CSF) mmol/L(reference values ¼ undetectable) nd 7 12 12
Glycine (CSF) mmol/L (reference values ¼ 7–11) nd 6 7 7
Serine (CSF) mmol/L (reference values ¼ 24–44) 32 28 29
Treatment with memantine no no M7 M19
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profile is not specific and is similar to the “cerebellar
cognitive affective syndrome” (Schmahmann and Sherman
1998; Botez-Marquard et al. 1994). MRI revealed atrophy
within the vermis and the anterior cerebellum. The lack of
more obvious abnormalities in other parts of the brain
suggests that myelination, dendritic arborisation and synapto-
genesis are not impaired.
Other diagnostic options such as post-hypoxic encepha-
lopathy or atypical neurodegeneration with brain iron
accumulation (NBIA) were discussed. The mild respiratory
difficulties at birth could hardly be responsible for signifi-
cant hypoxic brain damage. None of the morphological or
demyelinating sequelae usually reported in hypoxic brain
damage (Rees and Inder 2005) was detected on repetitive
brain imaging. In addition, we found no report of isolated
cerebellar atrophy with slowly progressive late-onset ataxia
occurring after brain anoxia in premature infants (Rees and
Inder 2005). Furthermore, the low morphometric parame-
ters at birth suggest that the clinical events were
conditioned intra uteri, before the eventual perinatal
hypoxia.
NBIA is a progressive extrapyramidal neurodegenera-
tion, responsible for at least three different clinical forms
always associated with abnormalities on MRI suggesting
iron accumulation (Gregory et al. 2009). Considering the
MRI images, an atypical NBIA due to PLA2G6 mutation
was suggested (A. Gregory, personal communication 2011).
Further genetic studies on PLA2G6 were not proposed with
a view to the insignificant signal differences on the brain
imaging in our patient compared to age-matched controls
and the recent genetic data in our patient (Bar-Joseph et al.
2012).
The glycine levels in plasma and CSF in our patient
were within the normal ranges except in the initial assay
(Table 1). Still, we are not certain whether this assay is
the appropriate measure of the potential pathological
mechanism of sarcosinemia.
So far, the pathogenesis of sarcosinemia remains
unexplained. The SarDH was initially identified in human
brain but has high hepatic expression. The SARDH gene
locus is on 9q34, which contains 21 exons and spans about
75 kb. A recent paper reports that our patient carries two
maternal alleles in the vicinity of the 9q34 (Bar-Joseph
et al. 2012). Even though no mutations were detected in the
SARDH gene, this maternal isodisomy could be responsible
for the sarcosinemia. These data may be helpful for early
diagnosis and adequate nutrition early in life.
The clinical manifestations of our patient developed in a
continuum of gradually impaired CNS dysfunctions of the
structures involved in the movement control and global
cognition rather than an acute perinatal event. We consider
that the underlying cerebellar involvement may be involved
in his cognitive profile. In light of these results, it seems
that sarcosinemia may lead to harmoniously small antenatal
size and premature birth, followed by slow evolution of
cognitive and neurological signs that affect daily living
functions and social integration. Our case adds some
additional evidence that sarcosinemia may be associated
to neurodevelopmental disability.
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